Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues.
The expression of CD97, a member of the EGF-TM7 family with adhesive properties, is proportional to the aggressiveness and lymph node involvement in thyroid tumors. CD97 has never been systematically investigated in other tumors. First, we examined colorectal carcinoma cell lines (n = 18) for CD97 expression and regulation. All cell lines were CD97-positive. The level of CD97 in each line correlated with migration and invasion in vitro. This result was confirmed in CD97-inducible Tet-off HT1080 cells. Transforming growth factor-beta, which inhibits proliferation in transforming growth factor-beta-sensitive LS513 and LS1034 cells, down-regulated CD97 in these cell lines. Examining CD97 during sodium butyrate-induced cell differentiation of Caco-2 cells, we could demonstrate a CD97-decreasing effect. Second, we screened 81 colorectal adenocarcinomas by immunohistology for expression of CD97. Normal colorectal epithelium is CD97-negative. Seventy-five of 81 of the carcinomas expressed CD97. The strongest staining for CD97 occurred in scattered tumor cells at the invasion front compared to cells located within solid tumor formations of the same tumor. Carcinomas with more strongly CD97-stained scattered tumor cells showed a poorer clinical stage as well as increased lymph vessel invasion compared to cases with uniform CD97 staining. In summary, CD97 expression correlates with dedifferentiation, migration, and invasion in colorectal tumor cell lines. Moreover, more strongly CD97-stained tumor cells at the invasion front of colorectal carcinomas indicate the involvement of the molecule in tumor migration and invasion.
Steinert
Matthias
M
Department of Surgery, University of Leipzig, Germany.
Wobus
Manja
M
Boltze
Carsten
C
Schütz
Alexander
A
Wahlbuhl
Mandy
M
Hamann
Jörg
J
Aust
Gabriela
G
D000730:Androstadienes / Q000494:pharmacology; D015703:Antigens, CD; D002087:Butyrates / Q000494:pharmacology; D018938:Caco-2 Cells; D002277:Carcinoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D002454:Cell Differentiation; D002465:Cell Movement; D015179:Colorectal Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005786:Gene Expression Regulation; D006801:Humans; D007420:Intestine, Large / Q000378:metabolism; D007700:Kinetics; D008562:Membrane Glycoproteins / Q000235:genetics / Q000378:metabolism*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D012334:RNA, Neoplasm / Q000096:biosynthesis; D043562:Receptors, G-Protein-Coupled; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D000077191:Wortmannin
C095004:ADGRE5 protein, human; D000730:Androstadienes; D015703:Antigens, CD; D002087:Butyrates; D004791:Enzyme Inhibitors; D008562:Membrane Glycoproteins; D000081082:Phosphoinositide-3 Kinase Inhibitors; D012334:RNA, Neoplasm; D043562:Receptors, G-Protein-Coupled; D016212:Transforming Growth Factor beta; D000077191:Wortmannin